Literature DB >> 29669167

Scoliosis in Fibrous Dysplasia/McCune-Albright Syndrome: Factors Associated With Curve Progression and Effects of Bisphosphonates.

Jason A Berglund1,2, Sri Harsha Tella1, Kaitlyn F Tuthill3, Lauren Kim4, Lori C Guthrie1, Scott M Paul5, Robert Stanton6, Michael T Collins1, Alison M Boyce1.   

Abstract

Scoliosis is a complication of fibrous dysplasia/McCune-Albright syndrome (FD/MAS); however, risk factors and long-term outcomes are unknown. Bisphosphonates are commonly used; however, it is unknown whether their use decrease the risk of progressive scoliosis. Clinical data from the National Institutes of Health (NIH) cohort study was reviewed. Cobb angles were measured, and variables associated with scoliosis progression were identified. Of 138 subjects with available radiographs, 84 (61%) had scoliosis, including 55 (65%) classified as mild (Cobb angle >10 to ≤30 degrees), 11 (13%) as moderate (>30 to ≤45 degrees), and 18 (22%) as severe (>45 degrees). Total skeletal disease burden was highly associated with scoliosis severity (p < 0.0001). Endocrinopathies associated with scoliosis included fibroblast growth factor 23 (FGF23)-mediated hypophosphatemia (p < 0.001) and hyperthyroidism (p < 0.001). Bone turnover markers, including osteocalcin and NTX-telopeptides, were associated with severe scoliosis (p < 0.01). Associations were identified between Cobb angle and functional metrics, including leg length discrepancy (p < 0.01), hip range of motion (p < 0.05), and strength of the gluteus medius and maximus (p < 0.01). Longitudinal analyses were conducted in 69 subjects who had serial radiographs over a median 4.9-year period (range, 0.9 to 14.7 years). Twenty-two subjects were treated with bisphosphonates; there was no difference in Cobb angle progression compared to untreated subjects (0.10 versus 0.53 degrees/year, p = 0.36). Longitudinal data was available for 10 of 12 subjects treated with spinal fusion; one had instrumentation failure, but in nine subjects Cobb angles were stable with 6.1 years of follow-up (range, 0.9 to 14.7 years). Two fatalities from scoliosis-associated restrictive lung disease occurred in subjects managed non-operatively. Scoliosis occurs frequently in patients with polyostotic FD, and may be potentially fatal. The primary risk factor for progressive scoliosis is total skeletal disease burden. Treatable features that contribute to scoliosis progression include leg length discrepancy, FGF23-mediated hypophosphatemia, and hyperthyroidism. Current data do not support routine use of bisphosphonates to prevent progression of spinal curvature. Spinal fusion is frequently effective in providing long-term stability, and may be lifesaving. Published 2018. This article is a U.S. Government work and is in the public domain in the USA. Published 2018. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  ANTIRESORPTIVES; CANCER; IMPLANTS; ORTHOPAEDICS; PRIMARY TUMORS OF BONE AND CARTILAGE; THERAPEUTICS

Mesh:

Substances:

Year:  2018        PMID: 29669167     DOI: 10.1002/jbmr.3446

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  12 in total

1.  Chiari I Malformation and Basilar Invagination in Fibrous Dysplasia: Prevalence, Mechanisms, and Clinical Implications.

Authors:  Kristen S Pan; John D Heiss; Sydney M Brown; Michael T Collins; Alison M Boyce
Journal:  J Bone Miner Res       Date:  2018-08-03       Impact factor: 6.741

Review 2.  Fibrous Dysplasia of Bone and McCune-Albright Syndrome: A Bench to Bedside Review.

Authors:  Iris Hartley; Maria Zhadina; Micheal T Collins; Alison M Boyce
Journal:  Calcif Tissue Int       Date:  2019-04-29       Impact factor: 4.333

3.  Long Bone Fractures in Fibrous Dysplasia/McCune-Albright Syndrome: Prevalence, Natural History, and Risk Factors.

Authors:  Raya E S Geels; Maartje E Meier; Amanda Saikali; Roula Tsonaka; Natasha M Appelman-Dijkstra; Alison M Boyce
Journal:  J Bone Miner Res       Date:  2021-11-17       Impact factor: 6.390

Review 4.  DIAGNOSIS OF ENDOCRINE DISEASE: Mosaic disorders of FGF23 excess: Fibrous dysplasia/McCune-Albright syndrome and cutaneous skeletal hypophosphatemia syndrome.

Authors:  Luis F de Castro; Diana Ovejero; Alison M Boyce
Journal:  Eur J Endocrinol       Date:  2020-05       Impact factor: 6.664

Review 5.  The Clinical Spectrum of McCune-Albright Syndrome and Its Management.

Authors:  Tiahna Spencer; Kristen S Pan; Michael T Collins; Alison M Boyce
Journal:  Horm Res Paediatr       Date:  2019-12-19       Impact factor: 2.852

6.  Burosumab treatment for fibrous dysplasia.

Authors:  Anne Gladding; Vivian Szymczuk; Bethany A Auble; Alison M Boyce
Journal:  Bone       Date:  2021-05-11       Impact factor: 4.626

7.  18 F-NaF PET/CT IMAGING IN FIBROUS DYSPLASIA OF BONE.

Authors:  Georgios Z Papadakis; Georgios C Manikis; Apostolos H Karantanas; Pablo Florenzano; Ulas Bagci; Kostas Marias; Michael T Collins; Alison M Boyce
Journal:  J Bone Miner Res       Date:  2019-05-22       Impact factor: 6.390

Review 8.  Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/MAS international consortium.

Authors:  Muhammad Kassim Javaid; Alison Boyce; Natasha Appelman-Dijkstra; Juling Ong; Patrizia Defabianis; Amaka Offiah; Paul Arundel; Nick Shaw; Valter Dal Pos; Ann Underhil; Deanna Portero; Lisa Heral; Anne-Marie Heegaard; Laura Masi; Fergal Monsell; Robert Stanton; Pieter Durk Sander Dijkstra; Maria Luisa Brandi; Roland Chapurlat; Neveen Agnes Therese Hamdy; Michael Terrence Collins
Journal:  Orphanet J Rare Dis       Date:  2019-06-13       Impact factor: 4.123

9.  Association between Bone Turnover Markers, Leptin, and Nutritional Status in Girls with Adolescent Idiopathic Scoliosis (AIS).

Authors:  Edyta Matusik; Jacek Durmala; Magdalena Olszanecka-Glinianowicz; Jerzy Chudek; Pawel Matusik
Journal:  Nutrients       Date:  2020-08-31       Impact factor: 5.717

Review 10.  Fibrous Dysplasia/McCune-Albright Syndrome: A Rare, Mosaic Disease of Gα s Activation.

Authors:  Alison M Boyce; Michael T Collins
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.